Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, with HER2 FISH Correlation: A Cohort of 112 Patients
Introduction. Recent trials demonstrated clinically significant benefits in HER2-nonamplified breast cancer with HER2-low expression using novel anti-HER2 antibody-drug conjugates. Thus, HER2-low breast cancer was proposed as a separate diagnostic entity. Herein, we reclassify HER2-negative cancers...
Saved in:
Main Authors: | Gokce Deniz Ardor (Author), Miglena K. Komforti (Author), Helena Hanna (Author), Onur Ibanoglu (Author), Abigail Lochala (Author), Aziza Nassar (Author) |
---|---|
Format: | Book |
Published: |
Hindawi-Wiley,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
HER 2 status in invasive breast cancer: Immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization
by: Hemlata S Shirsat, et al.
Published: (2012) -
Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer
by: Miaomiao Jia, et al.
Published: (2024) -
Inter-observer agreement in reporting HER 2 Neu protein over expression by immunohistochemistry
by: Ibrahim Al Haddabi, et al.
Published: (2014) -
The status of HER2 in colorectal carcinoma and the relation of HER2 with prognostic parameters and MSI
by: Ismail Saygin, et al.
Published: (2022) -
Correlation of Serum HER-2/neu Levels with Clinico-Pathological Variables and Tissue Immunohistochemistry in Breast Carcinoma
by: Islam Barkatullah, et al.
Published: (2021)